Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | GLS | O94925 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263495 | 0.79 | L3MBTL1 (0.46) | SMN1; SMN2RAB9ANPC1POLBL3MBTL1 | |
| SCHEMBL4771728 | 0.78 | SMN1; SMN2 (0.44) | TSHRSMN1; SMN2RAB9ANPC1GLS | |
| SCHEMBL20631846 | 0.75 | HSD17B10 (0.48) | TSHRSMN1; SMN2RAB9ANPC1GLS | |
| SCHEMBL11377836 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2RAB9ANPC1GLSL3MBTL1 | |
| SCHEMBL6303435 | 0.72 | SLC6A3 (0.39) | SMN1; SMN2RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL12752491 | 0.71 | SMN1; SMN2 (0.39) | TSHRSMN1; SMN2RAB9ANPC1GLS | |
| SCHEMBL22861048 | 0.71 | POLB (0.37) | TSHRSMN1; SMN2RAB9ANPC1GLS | |
| SCHEMBL6297776 | 0.69 | SMN1; SMN2 (0.38) | TSHRSMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL24259191 | 0.68 | GLS (0.48) | TSHRSMN1; SMN2RAB9ANPC1GLS | |
| SCHEMBL13398310 | 0.67 | SMN1; SMN2 (0.40) | TSHRSMN1; SMN2RAB9ANPC1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10988451-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10703733-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | TSHR 4426/4885SMN1; SMN2 1771/4885RAB9A 3188/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | TSHR 4426/4885SMN1; SMN2 1771/4885RAB9A 3188/4885 |
| US-20230312490-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | TSHR 4426/4885SMN1; SMN2 1771/4885RAB9A 3188/4885 |
| US-10703733-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | TSHR 4426/4885SMN1; SMN2 1771/4885RAB9A 3188/4885 |
| US-11643400-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | TSHR 4426/4885SMN1; SMN2 1771/4885RAB9A 3188/4885 |
| US-10988451-B2 | MCL-1 inhibitors | MCL1, BCL2L1, BCL2 | TSHR 4426/4885SMN1; SMN2 1771/4885RAB9A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.